Global Biosimilar Contract Manufacturing Market
Global Biosimilar Contract Manufacturing Market was valued at US$ 7.3 billion in 2021, estimated to reach US$ 15.68 billion in 2027, with a CAGR of 17.02% from 2022-2027.
This biosimilar is used in treating ophthalmology conditions, like Diabetic Macular Edema (DME), Macular Edema following Retinal Vein Occlusion; Neovascular Age-Related Macular Degeneration (AMD) Diabetic Retinopathy (DR), and Myopic Choroidal Neovascularization. Increasing number of biosimilar approvals are expected to profit the industry.
Market Drivers
The increase in outsourcing volume by biopharmaceutical industries, growing investments in research & development, and expansion in the services offered by the contract manufacturing organizations (CMOs) are the key driving factors for the biosimilar contract manufacturing market. Most biotechnology companies continue to outsource to contract manufacturing organizations to meet their fill-and-finish needs & reduce risk.
Some small biotechnology companies outsource their manufacturing needs since they do not have the in-house capacity, which helps obviate the need for capital expenditures & reduces business risk. These businesses are considered important consumers of Contract Manufacturing Organizations since they lack the necessary expertise to create sustainable manufacturing operations. Breakthrough technological inventions & discoveries in bioprocessing have aided contract service providers' growth by overcoming manufacturing challenges such as high production costs & the necessity for batch changeover. Such factors altogether drive the demand for biosimilar contract manufacturing market growth.
Market Restraints
Stringent regulatory requirements are a main restraint which expected to hamper the growth of global biosimilar contract manufacturing market over the forecast period. Also, logistics cost is another factor which may limit the growth of global biosimilar contract manufacturing market.
Market Segmentation
Global Biosimilar Contract Manufacturing Market is segmented into product such as Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins. By Production technology, market is segmented into Mammalian, and Non-Mammalian. Also, the market is segmented into application such as Oncology, Blood Disorders, Rheumatoid Arthritis, Others.
Regional Analysis
Global Biosimilar Contract Manufacturing Market is segmented into five regions such as North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.
Asia Pacific is expected to register the fastest CAGR over the forecast period due to the increase in aging population as well as the high prevalence of chronic & infectious diseases in the region, thus promoting the demand for cost-effective treatments.
Key Players
Boehringer Ingelheim Biopharmaceuticals GmbH, Lonza, Catalent, Inc., IQVIA Inc., Samsung Biologics, WuXi Biologics, Element Materials Technology, Rentschler Biopharma SE, Avid Bioservices, Inc., etc.
Market Taxonomy
By Product
By Production Technology
By Application
By Region
Global Biosimilar Contract Manufacturing Market
1 Introduction
1.1 Objective of the Study
1.2 Market definition
1.3 Market Scope
2 Research Methodology
2.1 Data Mining
2.2 Validation
2.3 Primary Interviews
2.4 List of Data Sources
3 Executive Summary
4 Global Biosimilar Contract Manufacturing Market Outlook
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
5 Global Biosimilar Contract Manufacturing Market, By Product
5.1 Y-o-Y Growth Comparison, By Product
5.2 Global Biosimilar Contract Manufacturing Market Share Analysis, By Product
5.3 Global Biosimilar Contract Manufacturing Market Size and Forecast, By Product
5.3.1 Recombinant Non-glycosylated Proteins
5.3.2. Recombinant Glycosylated Proteins
6 Global Biosimilar Contract Manufacturing Market, By Production Technology
6.1 Y-o-Y Growth Comparison, By Production Technology
6.2 Global Biosimilar Contract Manufacturing Market Share Analysis, By Production Technology
6.3 Global Biosimilar Contract Manufacturing Market Size and Forecast, By Production Technology
6.3.1. Mammalian
6.3.2 Non-Mammalian
7 Global Biosimilar Contract Manufacturing Market, By Application
7.1 Y-o-Y Growth Comparison, By Application
7.2 Global Biosimilar Contract Manufacturing Market Share Analysis, By Application
7.3 Global Biosimilar Contract Manufacturing Market Size and Forecast, By Application
7.3. 1. Oncology
7.3.2. Blood Disorders
7.3.3. Rheumatoid Arthritis
7.3.4. Others
8 Global Biosimilar Contract Manufacturing Market, By Region
8.1 Global Biosimilar Contract Manufacturing Market Share Analysis, By Region
8.2 Global Biosimilar Contract Manufacturing Market Share Analysis, By Region
8.3 Global Biosimilar Contract Manufacturing Market Size and Forecast, By Region
9 North America Biosimilar Contract Manufacturing Market Analysis and Forecast (2022-2027)
9.1 Introduction
9.2 North America Biosimilar Contract Manufacturing Market Share Analysis, By Product
9.3 North America Biosimilar Contract Manufacturing Market Size and Forecast, By Production Technology
9.4 North America Biosimilar Contract Manufacturing Market Size and Forecast, By Application
9.5 North America Biosimilar Contract Manufacturing Market Size and Forecast, By Country
9.5.1 U.S.
9.5.2 Canada
9.5.3 Mexico
10EuropeBiosimilar Contract Manufacturing Market Analysis and Forecast (2022-2027)
10.1 Introduction
10.2 Europe Biosimilar Contract Manufacturing Market Share Analysis, By Product
10.3 Europe Biosimilar Contract Manufacturing Market Size and Forecast, By Production Technology
10.4 Europe Biosimilar Contract Manufacturing Market Size and Forecast, By Application
10.5 Europe Biosimilar Contract Manufacturing Market Size and Forecast, By Country
10.5.1 Germany
10.5.2 France
10.5.3 UK
10.54. Rest of Europe
11Asia Pacific Biosimilar Contract Manufacturing Market Analysis and Forecast (2022-2027)
11.1 Introduction
11.2 Asia Pacific Biosimilar Contract Manufacturing Market Share Analysis, By Product
11.3 Asia Pacific Biosimilar Contract Manufacturing Market Size and Forecast, By Production Technology
11.4 Asia Pacific Biosimilar Contract Manufacturing Market Size and Forecast, By Application
11.5 Asia Pacific Biosimilar Contract Manufacturing Market Size and Forecast, By Country
11.5.1 China
11.5.2 Japan
11.5.3 India
11.5.4. Rest of Asia Pacific
12Latin America Biosimilar Contract Manufacturing Market Analysis and Forecast (2022-2027)
12.1 Introduction
12.2 Latin America Biosimilar Contract Manufacturing Market Share Analysis, By Product
12.3 Latin America Biosimilar Contract Manufacturing Market Size and Forecast, By Production Technology
12.4 Latin America Biosimilar Contract Manufacturing Market Size and Forecast, By Application
12.5 Latin America Biosimilar Contract Manufacturing Market Size and Forecast, Country
12.5.1. Brazil
12.5.2. Rest of Latin America
13Middle East Biosimilar Contract Manufacturing Market Analysis and Forecast (2022-2027)
13.1 Introduction
13.2 Middle East Biosimilar Contract Manufacturing Market Share Analysis, By Product
13.3 Middle East Biosimilar Contract Manufacturing Market Size and Forecast, By Production Technology
13.4 Middle East Biosimilar Contract Manufacturing Market Size and Forecast, By Application
13.5 Middle East Biosimilar Contract Manufacturing Market Size and Forecast, By Country
13.5.1. Saudi Arabia
13.5.2. UAE
13.5.3. Egypt
13.5.4. Kuwait
13.5.5. South Africa
14 Competitive Analysis
14.1 Competition Dashboard
14.2 Market share Analysis of Top Vendors
14.3 Key Development Strategies
15 Company Profiles
15.1 BOEHRINGER INGELHEIM BIOPHARMACEUTICALS GMBH
15.1.1 Overview
15.1.2 Offerings
15.1.3 Key Financials
15.1.4 Business Segment & Geographic Overview
15.1.5 Key Market Developments
15.1.6 Key Strategies
15.2. LONZA
15.2.1 Overview
15.2.2 Offerings
15.2.3 Key Financials
15.2.4 Business Segment & Geographic Overview
15.2.5 Key Market Developments
15.2.6 Key Strategies
15.3. CATALENT, INC.
15.3.1 Overview
15.3.2 Offerings
15.3.3 Key Financials
15.3.4 Business Segment & Geographic Overview
15.3.5 Key Market Developments
15.3.6 Key Strategies
15.4 IQVIA INC
15.4.1 Overview
15.4.2 Offerings
15.4.3 Key Financials
15.4.4 Business Segment & Geographic Overview
15.4.5 Key Market Developments
15.4.6 Key Strategies
15.5 SAMSUNG BIOLOGICS
15.5.1 Overview
15.5.2 Offerings
15.5.3 Key Financials
15.5.4 Business Segment & Geographic Overview
15.5.5 Key Market Developments
15.5.6 Key Strategies
15.6 WUXI BIOLOGICS
15.6.1 Overview
15.6.2 Offerings
15.6.3 Key Financials
15.6.4 Business Segment & Geographic Overview
15.6.5 Key Market Developments
15.6.6 Key Strategies
15.7 ELEMENT MATERIALS TECHNOLOGY
15.7.1 Overview
15.7.2 Offerings
15.7.3 Key Financials
15.7.4 Business Segment & Geographic Overview
15.7.5 Key Market Developments
15.7.6 Key Strategies
15.8 RENTSCHLER BIOPHARMA SE
15.8.1 Overview
15.8.2 Offerings
15.8.3 Key Financials
15.8.4 Business Segment & Geographic Overview
15.8.5 Key Market Developments
15.8.6 Key Strategies
15.9 BIOSERVICES, INC
15.9.1 Overview
15.9.2 Offerings
15.9.3 Key Financials
15.9.4 Business Segment & Geographic Overview
15.9.5 Key Market Developments
15.9.6 Key Strategies
